Filing Flows › Comparisons › BFRI vs STOK
Biofrontera vs Stoke Therapeutics: BFRI and STOK compared
Biofrontera is the larger company: $12.0M of revenue in its latest quarter (Q2 2026) against $11.3M for Stoke Therapeutics (Q3 2026). Biofrontera is growing faster (+33% against +6% a year earlier). Biofrontera is more profitable, with an operating margin of -4.4% against -686.9%.
Where the money goes: BFRI and STOK
Biofrontera (BFRI) · Q2 2026
Biofrontera, Q2 2026: revenue $12.0M (+33% year over year), operating margin -4.4%, net loss $604K, operating cash flow −$1.7M. The chart follows the revenue to costs, profit and cash.
Stoke Therapeutics (STOK) · Q3 2026
Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%, net loss $73.6M, operating cash flow −$62.7M. The chart follows the revenue to costs, profit and cash.
| Biofrontera (BFRI) | Stoke Therapeutics (STOK) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $12.0M | $11.3M |
| Revenue growth, Y/Y | +33% | +6% |
| Operating margin | -4.4% | -686.9% |
| Net earnings | −$604K | −$73.6M |
| Net margin | -5.0% | -654.3% |
| Operating cash flow | −$1.7M | −$62.7M |
Questions
Which is bigger, Biofrontera or Stoke Therapeutics?
Biofrontera is the larger company: $12.0M of revenue in its latest quarter (Q2 2026) against $11.3M for Stoke Therapeutics (Q3 2026).
Is Biofrontera or Stoke Therapeutics growing faster?
Biofrontera is growing faster (+33% against +6% a year earlier).
Which is more profitable, Biofrontera or Stoke Therapeutics?
Biofrontera is more profitable, with an operating margin of -4.4% against -686.9%.
More: Biofrontera earnings · how Biofrontera makes money · Stoke Therapeutics earnings · how Stoke Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.